Randomized, placebo-controlled study of a new botulinum toxin type a for treatment of glabellar lines: Efficacy and safety

Fredric Brandt, Neil Swanson, Leslie Baumann, Barbara Huber

Research output: Contribution to journalArticle

75 Citations (Scopus)

Abstract

BACKGROUND A new botulinum toxin type A (BoNT-A) has been assessed in the United States for treatment of glabellar lines. In April 2009, the US FDA approved the Biologics License Application for a new US formulation of BoNT-A (Dysport [abobotulinumtoxinA]; Medicis Aesthetics Inc., Scottsdale, AZ). OBJECTIVE To compare efficacy and safety of a single treatment of BoNT-A with placebo in subjects with moderate to severe glabellar lines. METHODS AND MATERIALS One hundred fifty-eight subjects with moderate to severe glabellar lines were randomized 2:1 to receive 50 U of BoNT-A (n=105) or placebo (n=53). Responders were defined as having no or mild glabellar lines at 30 days posttreatment according to investigator and subject assessments (co-primary endpoint) using the validated Glabellar Line Scale Score at maximum frown. Subject diaries were used to document onset of effect. When conducting the research, the authors conformed to the ethical guidelines of the 1975 Declaration of Helsinki. RESULTS According to investigator assessment, the proportion of responders to BoNT-A at Day 30 was 89.5%, versus 7.5% for placebo (p

Original languageEnglish (US)
Pages (from-to)1893-1901
Number of pages9
JournalDermatologic Surgery
Volume35
Issue number12
DOIs
StatePublished - Dec 2009

Fingerprint

Type A Botulinum Toxins
Botulinum Toxins
Placebos
Safety
Helsinki Declaration
Research Personnel
Therapeutics
Licensure
Biological Products
Esthetics
Guidelines
Research

ASJC Scopus subject areas

  • Dermatology
  • Surgery

Cite this

Randomized, placebo-controlled study of a new botulinum toxin type a for treatment of glabellar lines : Efficacy and safety. / Brandt, Fredric; Swanson, Neil; Baumann, Leslie; Huber, Barbara.

In: Dermatologic Surgery, Vol. 35, No. 12, 12.2009, p. 1893-1901.

Research output: Contribution to journalArticle

Brandt, Fredric ; Swanson, Neil ; Baumann, Leslie ; Huber, Barbara. / Randomized, placebo-controlled study of a new botulinum toxin type a for treatment of glabellar lines : Efficacy and safety. In: Dermatologic Surgery. 2009 ; Vol. 35, No. 12. pp. 1893-1901.
@article{ac007af546fe46d9929b84835892015c,
title = "Randomized, placebo-controlled study of a new botulinum toxin type a for treatment of glabellar lines: Efficacy and safety",
abstract = "BACKGROUND A new botulinum toxin type A (BoNT-A) has been assessed in the United States for treatment of glabellar lines. In April 2009, the US FDA approved the Biologics License Application for a new US formulation of BoNT-A (Dysport [abobotulinumtoxinA]; Medicis Aesthetics Inc., Scottsdale, AZ). OBJECTIVE To compare efficacy and safety of a single treatment of BoNT-A with placebo in subjects with moderate to severe glabellar lines. METHODS AND MATERIALS One hundred fifty-eight subjects with moderate to severe glabellar lines were randomized 2:1 to receive 50 U of BoNT-A (n=105) or placebo (n=53). Responders were defined as having no or mild glabellar lines at 30 days posttreatment according to investigator and subject assessments (co-primary endpoint) using the validated Glabellar Line Scale Score at maximum frown. Subject diaries were used to document onset of effect. When conducting the research, the authors conformed to the ethical guidelines of the 1975 Declaration of Helsinki. RESULTS According to investigator assessment, the proportion of responders to BoNT-A at Day 30 was 89.5{\%}, versus 7.5{\%} for placebo (p",
author = "Fredric Brandt and Neil Swanson and Leslie Baumann and Barbara Huber",
year = "2009",
month = "12",
doi = "10.1111/j.1524-4725.2009.01235.x",
language = "English (US)",
volume = "35",
pages = "1893--1901",
journal = "Dermatologic Surgery",
issn = "1076-0512",
publisher = "Wiley-Blackwell",
number = "12",

}

TY - JOUR

T1 - Randomized, placebo-controlled study of a new botulinum toxin type a for treatment of glabellar lines

T2 - Efficacy and safety

AU - Brandt, Fredric

AU - Swanson, Neil

AU - Baumann, Leslie

AU - Huber, Barbara

PY - 2009/12

Y1 - 2009/12

N2 - BACKGROUND A new botulinum toxin type A (BoNT-A) has been assessed in the United States for treatment of glabellar lines. In April 2009, the US FDA approved the Biologics License Application for a new US formulation of BoNT-A (Dysport [abobotulinumtoxinA]; Medicis Aesthetics Inc., Scottsdale, AZ). OBJECTIVE To compare efficacy and safety of a single treatment of BoNT-A with placebo in subjects with moderate to severe glabellar lines. METHODS AND MATERIALS One hundred fifty-eight subjects with moderate to severe glabellar lines were randomized 2:1 to receive 50 U of BoNT-A (n=105) or placebo (n=53). Responders were defined as having no or mild glabellar lines at 30 days posttreatment according to investigator and subject assessments (co-primary endpoint) using the validated Glabellar Line Scale Score at maximum frown. Subject diaries were used to document onset of effect. When conducting the research, the authors conformed to the ethical guidelines of the 1975 Declaration of Helsinki. RESULTS According to investigator assessment, the proportion of responders to BoNT-A at Day 30 was 89.5%, versus 7.5% for placebo (p

AB - BACKGROUND A new botulinum toxin type A (BoNT-A) has been assessed in the United States for treatment of glabellar lines. In April 2009, the US FDA approved the Biologics License Application for a new US formulation of BoNT-A (Dysport [abobotulinumtoxinA]; Medicis Aesthetics Inc., Scottsdale, AZ). OBJECTIVE To compare efficacy and safety of a single treatment of BoNT-A with placebo in subjects with moderate to severe glabellar lines. METHODS AND MATERIALS One hundred fifty-eight subjects with moderate to severe glabellar lines were randomized 2:1 to receive 50 U of BoNT-A (n=105) or placebo (n=53). Responders were defined as having no or mild glabellar lines at 30 days posttreatment according to investigator and subject assessments (co-primary endpoint) using the validated Glabellar Line Scale Score at maximum frown. Subject diaries were used to document onset of effect. When conducting the research, the authors conformed to the ethical guidelines of the 1975 Declaration of Helsinki. RESULTS According to investigator assessment, the proportion of responders to BoNT-A at Day 30 was 89.5%, versus 7.5% for placebo (p

UR - http://www.scopus.com/inward/record.url?scp=71549146072&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=71549146072&partnerID=8YFLogxK

U2 - 10.1111/j.1524-4725.2009.01235.x

DO - 10.1111/j.1524-4725.2009.01235.x

M3 - Article

C2 - 19549186

AN - SCOPUS:71549146072

VL - 35

SP - 1893

EP - 1901

JO - Dermatologic Surgery

JF - Dermatologic Surgery

SN - 1076-0512

IS - 12

ER -